BINDING MEMORANDUM OF UNDERSTANDINGMemorandum of Understanding • July 29th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • England
This Binding Memorandum of Understanding (“MOU”) is effective as of 28 July 2016 (“Effective Date”) and entered into by and between PharmaCyte Biotech, Inc.(“PharmaCyte”), a Nevada corporation with its principal place of business at 12510 Prosperity Drive, Suite 310, Silver Spring, Maryland 20904 USA, and Austrianova Singapore Pte Ltd (“Austrianova”), a Singapore corporation, with its principal place of business at 3 Biopolis Way #05-19, Synapase, Singapore, 138668. PharmaCyte and Austrianova are referred to in this MOU each as a “Party” and collectively as the “Parties.”
Second Amendment to Licensing AgreementLicensing Agreement • July 29th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This Second Amendment to Licensing Agreement ("Second Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc.,formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte Ltd ("Licensor") to amend, effective as of 19 October 2015, the Licensing Agreement between the Parties dated as of 1 December 2014 ("Licensing Agreement") as set forth below . Defined terms in the Licensing Agreement have the same meaning as the terms in this Second Amendment.
Kenneth L. Waggoner Chief Executive Officer and Director Pharmacyte Biotech Australia Pty Ltd Level 15 Brisbane, QLD 4001 Australia By email: kwaggoner@PharmaCyte.com RE: VARIATION TO LICENCE AGREEMENT DATED 10 OCTOBER 2014 Dear Ken,License Agreement • July 29th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
We refer to recent discussions regarding the need to clarify several terms and correct the named Licensee in the License Agreement between University of Technology, Sydney and Pharmacyte Biotech Australia Pyt Ltd, formerly Nuvilex Australia Pty Ltd, made on 10 October 2014 ("License Agreement").
First Amendment to Licensing AgreementLicensing Agreement • July 29th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This First Amendment to Licensing Agreement ("First Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte Ltd ("Licensor”) to amend, effective as of 24 June 2016, the Licensing Agreement between the parties entered into as of June 25th, 2013 ("Licensing Agreement") as follows.
First Amendment to Licensing AgreementLicensing Agreement • July 29th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This First Amendment to Licensing Agreement ("First Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. ("Licensee") and Austrianova Singapore Pte Ltd ("Licensor") to amend, effective as of June 30, 2015, the Licensing Agreement between the parties dated as of 1 December 2014 ("Licensing Agreement") as follows. The defined terms in the Licensing Agreement have the same meaning as the terms in this First Amendment.
